General characteristics of cancer randomised controlled trials including elderly patients
Variable | Category | Total (n=72) |
International (if more than one country) | No | 48 (66.7) |
Yes | 24 (33.3) | |
Industry supported (fully or in part) | No | 35 (48.6) |
Yes | 37 (51.4) | |
Disease stage | Only metastatic/advanced | 35 (48.6) |
Only non-metastatic/local | 27 (37.5) | |
Both | 8 (11.1) | |
Unclear | 2 (2.8) | |
Overall study sample size | ≤200 | 33 (45.8) |
>200 | 39 (54.2) | |
Secondary paper on PRO | No | 51 (70.8) |
Yes | 21 (29.2) | |
Year of publication | 2004–2010 | 37 (51.4) |
2011–2019 | 35 (48.6) | |
Type of treatment used* | Radiotherapy | 11 (15.3) |
Surgery | 8 (11.1) | |
Chemotherapy | 26 (36.1) | |
Targeted therapy | 9 (12.5) | |
Hormonal therapy | 26 (36.1) | |
Other | 14 (19.4) | |
PRO endpoint | Primary | 20 (27.8) |
Secondary | 52 (72.2) |
*More than one option could be chosen.
PRO, patient-reported outcome.